Rhenman & Partners Asset Management AB
Annual return
—
SPY
—
Alpha
—
Invested
$810.5M
Holdings
86
Trades YTD
0
Performance · Fund vs SPY
Cumulative return · quarterly snapshotsIn development
Quarterly performance not yet computed for this fund.
The metrics pipeline computes return / SPY benchmark / alpha per quarter from this fund's 13F holdings and the SPY adj-close. It hasn't produced enough quarters here yet — the chart fills in automatically once at least two are on record.
Top holdings · current snapshot
Source: 13F-HR01
$BSX
BOSTON SCIENTIFIC CORP
Q4 2025: Sold 1.6% (438.0k → 431.2k shares)
4.8%
02
$REGN
REGENERON PHARMACEUTICALS
Q4 2025: Increased +70.1% (36.1k → 61.4k shares)
4.6%
03
$LLY
LILLY ELI & CO
Q4 2025: Sold 21.0% (53.4k → 42.2k shares)
3.8%
04
$INSM
INSMED INC
Q4 2025: Sold 13.9% (131.9k → 113.6k shares)
3.2%
05
$CVS
CVS HEALTH CORP
Q4 2025: Increased +21.0% (277.4k → 335.5k shares)
3.0%
06
$GILD
GILEAD SCIENCES INC
Q4 2025: Increased +57.4% (80.2k → 126.2k shares)
2.9%
07
$TMO
THERMO FISHER SCIENTIFIC INC
Q4 2025: Increased +12.0% (30.0k → 33.6k shares)
2.5%
08
$BIIB
BIOGEN INC
Q4 2025: Increased +67.9% (55.0k → 92.4k shares)
2.5%
09
$VRTX
VERTEX PHARMACEUTICALS INC
Q4 2025: Sold 27.1% (47.0k → 34.3k shares)
2.4%
10
$ALHC
ALIGNMENT HEALTHCARE INC
Q4 2025: Sold 31.8% (1.48M → 1.01M shares)
2.3%
Recent trades · Last 90 days
No Form 4 / 13D / 13G trade events on file in the recent window. 13F filers report position snapshots quarterly rather than per-trade events, so this section is most useful for managers who also file Form 4 or 13D/G.
Source data: SEC EDGAR · 13F-HR filings · Last refreshed 09:01 UTC.